全球视野独到创意

KAYAKU spirit是日本化药集团的应有形象(即企业愿景)。
作为实现KAYAKU spirit的企业活动有CSR(Corporate Social
Responsibility)经营。同时作为开展KAYAKU spirit的行动规范,制定了
集团行働指南、日本化药集团行为宪章•行为基准。

What's New

2023/12/15
NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
2023/10/19
Updated information of sustainability
2023/10/18
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/09/25
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. PDF
2022/11/16
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody PDF

投资者关系

投资者关系资讯

2016 NIPPON KAYAKU 100th ANNIVERSARY
GO TO Website (English)
PageTop
我们的事业
研究开发
公司信息
全球网络
股东・投资者信息(English)
可持续发展(English)